What H1's $40 Million Investment Means for Drug Development

A healthcare data company called H1 has received $40 million in funding from CVS Health Ventures. The investment highlights a growing need among pharmaceutical companies for better tools to find and connect with doctors who conduct clinical trials — the tests that verify whether new drugs are safe and effective.

What H1 Does

H1 runs a database that collects information about doctors, researchers, and medical experts. Pharmaceutical companies use this data to find the right investigators to run clinical trials, identify influential doctors for advisory work, and locate specialists to teach other doctors about new treatments.

The platform gathers structured information about doctors' specialties, their research experience, what they've published, and where they work. It also uses artificial intelligence to read through medical papers, patents, and clinical trial records to find connections between researchers and new treatment areas.

Think of it like a sophisticated address book and search engine combined — instead of finding people by name or location, you find them by their expertise and research interests.

Why CVS Health Is Investing

CVS Health Ventures is the investment arm of CVS, the pharmacy and health insurance company. They are betting that H1's technology will become valuable to their business. CVS operates about 9,000 pharmacy locations and insures roughly 34 million people through its Aetna division.

CVS likely sees an opportunity here. When pharmaceutical companies run clinical trials, they need patients to participate. CVS's pharmacies and insurance plans give them access to large populations of patients. Combined with H1's ability to find the right doctors to run trials, this could become a powerful combination.

The Bigger Picture

Clinical trials are expensive — they typically cost millions of dollars per study. Pharmaceutical companies are always looking for ways to run trials faster and cheaper. Finding the right doctors in the right locations, quickly, is a big part of reducing those costs.

There is also a practical shift happening in how trials work. Regulators now want trials to include more diverse populations — different races, ages, and geographic regions. H1's data tools help identify doctors who serve different communities and can find patients from underrepresented groups.

H1 is not alone in this space. Several other companies offer similar services. But the market is still developing, and there is room for multiple players to succeed by doing different things well — offering better data, easier-to-use software, or stronger connections to the medical community.

The broader context here is worth noting: when enterprise software markets get established, they often consolidate over time. Companies that start by doing one thing well — like identifying trial investigators — eventually need to expand to offer a full suite of tools. H1 will likely face this pressure as it grows. Whether the company can make that transition successfully remains an open question.

What Comes Next

The CVS Health partnership opens some interesting possibilities. CVS's MinuteClinic locations (the walk-in clinics in CVS pharmacies) could become sites where clinical trials are conducted. Patients taking complex medications through CVS's specialty pharmacy could be identified as good candidates for follow-up studies.

More ambitiously, CVS collects a lot of data about patient outcomes from its pharmacy and insurance operations. If that data is combined with H1's doctor and researcher information, pharmaceutical companies could get a fuller picture — not just who the best investigators are, but what real-world results look like for drugs already on the market.

H1 will need to grow carefully. Healthcare data is sensitive, and laws in the U.S. and Europe protect how it can be collected and used. The company must keep data accurate as it expands internationally, since licensing requirements and professional registries differ from country to country.

The company also needs to keep improving its artificial intelligence tools to stay ahead of competitors. Being able to identify emerging research areas, predict which doctors might be interested in particular studies, and spot new collaboration opportunities will be crucial for H1's success.